Santarus PPI could be future Merck switch
This article was originally published in The Tan Sheet
Executive SummaryMerck's Schering-Plough consumer products unit would have OTC switch rights to a Santarus dual-buffer prescription proton pump inhibitor if FDA approves it under the Zegerid brand. The agency approved Santarus' immediate-release omeprazole/sodium bicarbonate/magnesium hydroxide prescription drug for treatment of heartburn and other symptoms of gastroesophageal reflex disease in 20-mg and 40-mg doses, the San Diego firm said Dec. 4. If FDA approves a new drug application supplement requesting the drug's name include the Zegerid brand, as Santarus expects, Merck can apply to switch it to OTC, a Santarus spokeswoman said. The Rx announcement follows FDA's approval of Zegerid OTC, set to launch in 2010 (1"The Tan Sheet" Dec. 7, 2009)
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.